Trial Profile
BILAG Biologics Prospective Cohort: The Use of Novel Biological Therapies in the Treatment of Systemic Lupus Erythematosus (SLE)
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 12 Jul 2023
Price :
$35
*
At a glance
- Drugs Azathioprine (Primary) ; Mycophenolate mofetil (Primary) ; Antirheumatics; Belimumab; Cyclophosphamide; Immunomodulators; Immunosuppressants; Rituximab
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; Biomarker; Therapeutic Use
- Acronyms BILAG-BR
- 03 Jun 2023 Results of all-cause mortality rate (MR) and the incidence of cancer in SLE patients receiving biologic and standard of care therapies, presented at the 24th Annual Congress of the European League Against Rheumatism
- 03 Jun 2023 Results assessing differential response of patients with moderate-severe SLE in the UK by ethnic background, presented at the 24th Annual Congress of the European League Against Rheumatism.
- 04 Jun 2022 Results assessing COVID-19 infections, hospitalisation and recovery in a real-world cohort of patients with moderate to severe SLE presented at the 23rd Annual Congress of the European League Against Rheumatism